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1. Introduction 
Neonatal epileptic encephalopathy (NEE) is a seizure disorder that occurs within hours 
from birth and arises from central nervous system (CNS) dysfunctions of various origins, 
including metabolic or inflammatory conditions, abnormalities of brain structure and 
cerebrovascular diseases. In some rare circumstances, NEE is refractory to conventional 
antiepileptic drugs (AEDs) but responds very well to treatment with vitamin B6 in the form 
of either pyridoxine (PN) or pyridoxal 5’-phosphate (PLP) [1-7]. Vitamin B6 exists in all 
organisms in the form of six vitamers but only PLP is the biologically active form acting as a 
cofactor for many enzymes (Figure 1.). 
Vitamin B6-dependent NEE derives from a deficiency of cellular PLP; either due to inborn 
errors in enzymes, such as pyridoxine 5’-phosphate oxidase (PNPOx) and pyridoxal kinase 
(PL kinase), involved in the PLP salvage pathway or from inherited mutations in other 
enzymes, such as α-aminoadipic semialdehyde dehydrogenase (also known as antiquitin), 
involved in other metabolic pathways, which lead to the accumulation of intermediates that 
react with PLP, reducing its availability. 
Clinical phenotypes observed in vitamin B6-dependent NEE patients may include fetal 
distress, hypoglycemia, acidosis, anemia, and asphyxia [2,5-7]. The health state of untreated 
patients may undergo progressive deterioration, which can lead to death within weeks. 
Surviving children are usually mentally retarded and are dependent on vitamin B6 to 
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control the disease. Several known cases of B6-dependent NEE, however do not or only 
mildly manifest some of the above clinical features, and are characterized by mild to 
moderate developmental delay. 
This chapter will review the molecular mechanisms of how in-born errors in PNPOx or 
antiquitin affect PLP levels in the cell and lead to NEE. We will also review important 
clinical and general features associated with PLP dependent NEE, and provide some 
directions for clinicians to diagnose and treat or manage the disease.  
2. Vitamin B6  
There are six B6 vitamers, including the primary forms pyridoxal (PL), pyridoxine (PN), and 
pyridoxamine (PM), and their phosphorylated derivatives PLP, pyridoxine 5’-phosphate 
(PNP) and pyridoxamine 5’-phosphate (PMP) (Figure. 1). Pyridoxal 5’-phosphate, the active 
form of vitamin B6 serves as a cofactor for over 160 vitamin B6 dependent enzymes (or PLP-
dependent enzymes) involved in amino acid metabolism (e.g. degradation of threonine and 
glycine), neurotransmitter biosynthesis, biologically active amine biosynthesis, lipid 
metabolism, carbohydrate breakdown, heme synthesis, nucleic acid synthesis and several 
other metabolic pathways [8,9]. 
 
Fig. 1. Structures of B6 vitamers 
2.1 Vitamin B6 metabolism 
Unlike microorganisms and plants, animals cannot synthesize PLP from small metabolites 
by a de novo pathway and require the dietary B6 vitamers, pyridoxal, pyridoxine, or 
pyridoxamine (Figure 1), for the synthesis of PLP via a so-called salvage pathway [10]. 
Enzymes which are critical for this salvage pathway are PL kinase, PNPOx and several 
different phosphatases (Figure 2). 
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PL kinase catalyzes the phosphorylation of the 5’-alcohol group of PN, PM, and PL to form 
PNP, PMP, and PLP, respectively (Figures 1 and 2). Both PNP and PMP are subsequently 
converted to PLP in an FMN-dependent oxidative process catalyzed by PNPOx (Figures 2 
and 3). PLP adds to newly synthesized apo-B6 enzymes converting them to the catalytically 
active holo-B6 enzymes. Typically, PLP is then released during protein turnover of B6 
enzymes and is converted to PL by cellular phosphatases, followed by re-phosphorylation 
to PLP by PL kinase [10,11].  
 
Fig. 2. The PLP salvage pathway 
 
Fig. 3. Conversion of PNP (or PMP) to PLP by PNPOx 
Mammals acquire B6 vitamers via intestinal absorption (Figure 4) and convert them into PLP 
through the salvage pathway (Figure 2). B6 vitamers are absorbed from food and from the 
microflora, which normally colonizes the large intestine. In animal-derived foods, vitamin 
B6 is mainly present as PLP, associated to glycogen phosphorylase, and in smaller amounts 
as PMP, while in plants it is present as PN and PN-5’-beta-D-glucoside [12]. PN-5’-beta-D-
glucoside appears to have reduced availability because of the need for hydrolysis by an 
intestinal glucosidase [13]. In human breast milk, vitamin B6 is present as PLP and PL [14]. 
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The form of vitamin B6 that is usually employed to fortify foods is pyridoxine 
hydrochloride, since this is the most commercially convenient form. 
Once ingested (Figure 4), PLP, PNP and PMP are dephosphorylated by the ecto-enzyme 
tissue-specific intestinal phosphatase, prior to absorption from the upper small intestine by 
a carrier-mediated system [15]. The portal circulation delivers PM, PN and PL to the liver, 
where they are phosphorylated by PL kinase. PNP and PMP are then both oxidized to PLP 
by PNPOx. PLP must return to the blood stream in order to reach all tissues. Albumin-
bound PLP represents about 60% of circulating vitamin B6, with PN, PM and PL making up 
the remaining part [16]. While dephosphorylated B6 vitamers can enter the cells and pass the 
blood-brain barrier, PLP needs to be dephosphorylated again. Tissue-specific phosphatases, 
expressed in placenta and germ cells [17,18], and the tissue-nonspecific alkaline phosphatase 
(TNAP) are membrane-associated enzymes responsible for this step. PL is the vitamer form 
that is mainly acquired by neurons; once formed by TNAP at the choroid plexus, PL is 
transported into the cerebrospinal fluid by an active transport mechanism and crosses the 
neuron plasma membranes to be re-phosphorylated in the cells [16]. In the cytoplasm, PL, 
PN and PM are converted into the 5’-phosphorylated vitamers by PL kinase, while PNPOx 
converts PNP and PMP into PLP. 
 
Fig. 4. Vitamin B6 transport in human organs. 
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The expression of mRNA of all enzymes of the salvage pathway is ubiquitous, but is 
highly regulated at the level of transcription in a tissue-specific manner. While PL kinase 
is expressed in all tissues, although with the presence of isoforms [19], the major sites of 
PNPOx expression are liver, skeletal muscle and kidneys; PNPOx is also present, to a 
lesser extent, in the brain, in particular in the cerebral cortex [20]. Remarkably, PNPOx 
activity seems to be absent in liver and in neurally derived tumors [21,22]. It should be 
emphasized that the pool of free PLP in vivo must be maintained at a very low level in the 
body, to prevent toxic buildup. In fact, PLP being a very reactive aldehyde, easily 
combines with amines and thiols in the cell [23]. This characteristic has been related to the 
neurotoxic effect of excess consumption of vitamin B6 [24], even at a dosage of 200 
mg/day. The current recommended dietary allowance for B6 is 1-2 mg/day for adult 
individuals. People taking high doses of B6 are known to develop acute, profound and 
permanent sensory neuropathy, and in some instances motor neuropathy and damage of 
the central nervous system [25]. High doses of PLP are also found to induce convulsion in 
animal studies; suggested to be caused by formation of a Schiff base between PLP and a 
crucial lysine residue located in an extracellular loop of the GABA receptor [26]. PLP  
has also been reported to inhibit phenol sulfotransferase, an important detoxification 
enzyme [27]. 
One mechanism involved in PLP homeostasis is the regulation of its rate of production by 
PL kinase and PNPOx. Interestingly, it has been shown that both enzymes are able to bind 
their reaction product, PLP, and that their activity is finely regulated by it. Inhibition of 
PNPOx activity by the PLP product has been observed in the E. coli enzyme, with a Ki of 8 
µM [28]. Also, substrate inhibition of E. coli PL kinase by MgATP has been observed in the 
presence of either PNP or PLP [29]. A concurring mechanism for maintaining low levels of 
free PLP is expected to be its dephosphorylation by phosphatases. Catalytic conversion of 
pyridoxal to 4-pyridoxic acid by aldehyde oxidases and NAD-dependent dehydrogenases 
also keeps the level of PLP low [30]. These regulatory mechanisms keep the concentration of 
free PLP as low as 1 µM in eukaryotic cells [31]. 
The low free PLP concentration in the cell is not believed to be sufficient to allow for 
spontaneous formation of holo-B6 enzymes [31,32] and raises the intriguing question of how 
PLP is actually delivered to the apoenzymes that use it as a cofactor. The importance of 
vitamin B6 in several cellular processes and in the onset of different pathologies should also 
be looked at from this new perspective. Studies on PNPOx and PL kinase suggest that once 
PLP is formed by these enzymes, it is unlikely to be released into solution, where it could be 
sequestered and/or dephosphorylated by phosphatases, and that it could be rather directly 
channeled to apo-B6 enzymes [32-34]. Failure to maintain a correct tuning between PLP 
biosynthesis and degradation, transport to peripheral tissues and delivery to newly formed 
B6 enzymes might end up in vitamin B6-associated pathogenesis. The salvage pathway is 
very efficient, resulting in only small amounts of vitamin B6 being required in the diet. 
Vitamin B6 deficiency is rare in humans receiving a normal diet.  
2.2 PLP-dependent enzymes and brain function 
The role of PLP-dependent enzymes in brain function is vital since the synthesis of several 
neurotransmitters, including D-serine, D-aspartate, L-glutamate, glycine, γ-aminobutyric 
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acid (GABA), serotonin, epinephrine, norepinephrine, histamine and dopamine is 
dependent on these enzymes. For example, branched-chain amino acid aminotransferase 
(BCAT), a PLP-dependent enzyme, catalyzes the transamination of essential branched-chain 
amino acids, such as leucine and valine, to form L-glutamate. L-Glutamate is considered to 
be one of the major excitatory signals in the mammalian central nervous system and is 
important for cognition, learning and memory. Low or abnormal levels have been 
implicated in Alzheimer's, Parkinson's, Huntington's, and Tourette's diseases [35-39]. L-
Glutamate also serves as a precursor for the formation of GABA, catalyzed by the PLP-
dependent enzyme glutamate decarboxylase (GAD). GABA is a major inhibitory 
neurotransmitter in the mammalian CNS. Low levels of GABA have been implicated in 
symptoms associated with epilepsy, convulsions, Parkinson’s, Alzheimer’s and 
Huntington’s diseases [40-43]. The PLP-dependent enzyme DOPA decarboxylase (also 
known as aromatic L-amino acid decarboxylase (AAAD)) catalyzes the synthesis of 
dopamine via decarboxylation of L-3,4-dihydroxyphenylalanine (L-DOPA). Dopamine 
serves as a precursor for norepinephrine and epinephrine. AAAD also catalyzes the 
synthesis of serotonin via decarboxylation of L-5-hydroxytryptophan. Low levels of 
dopamine and serotonin have been involved in clinical disorders, including Parkinson’s 
disease and Attention Deficit Hyperactivity Disorder (ADHD) [44,45]. The PLP-dependent 
enzyme serine racemase catalyzes the direct racemization of L-serine to D-serine. 
Endogenous D-serine is required for physiological NMDA (N-methyl D-aspartate) 
neurotransmission, neuronal plasticity, memory and learning [46]. Histidine decarboxylase 
(HDC), another PLP-dependent enzyme, is responsible for the catalytic conversion of L-
histidine to histamine. Histamine plays important roles in a number of physiological 
processes, among them as a neurotransmitter involved in memory [47,48]. Glycine is formed 
from L-serine by the PLP-dependent serine hydroxymethyltransferase and is degraded by 
the glycine cleavage system, of which one of the four protein components is glycine 
decarboxylase, another PLP-dependent enzyme. Glycine is also a neurotransmitter, acting as 
both inhibitory and excitatory functions within the CNS [49]. PLP-dependent enzymes also 
take part in the kynurenine oxidative pathway of tryptophan degradation, whose catabolic 
intermediates (kynurenic acid, 3-hydroxykynurenine and quinolinic acid) are involved in 
the physiological tuning of the CNS and in the etiogenesis and progression of several 
human neurodegenerative disorders [50,51]. 
It is obvious that inadequate PLP levels will result in loss of activity of B6 enzymes, leading 
to a significant decrease of some or several neurotransmitters. As mentioned above, PLP, as 
well as the other phosphorylated forms of vitamin B6, do not easily cross the blood–brain 
barrier; therefore PLP must be synthesized within the brain tissues from the non-
phosphorylated vitamers. Thus, the potential for PLP depletion in the brain is likely to occur 
with inactivation of the B6 salvage pathway enzymes [31]. Moreover, because apo-B6 
enzymes in the brain compete for the available PLP, even a modest decrease in PLP 
availability could have more dire consequences on brain function than would be expected. 
Those apo-B6 enzymes that bind PLP with higher affinity may get most of the available PLP. 
As an example, DOPA decarboxylase is known to be drastically affected by PLP deficiency 
[52]. Consistently, inactivation of DOPA decarboxylase has been used in the past as a model 
for determining B6 status.  
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2.3 Pyridoxine 5’-phosphate oxidase (PNPOx) 
PNPOx is a flavin mononucleotide (FMN)-dependent enzyme, catalyzing the terminal step 
in the de novo vitamin B6 biosynthesis pathway in E. coli. The enzyme is also part of the 
salvage pathway in E. coli and mammalian cells [10,11,28,53-61]. FMN is a phosphorylated 
form of vitamin B2 (riboflavin). The catalytic mechanism of PNPOx involves direct hydride 
transfer from the 4’ hydroxyl group of PNP or the 4’ amino group of PMP to FMN to form 
PLP and FMNH2, respectively (Figure 3). Oxidized FMN is then regenerated by the transfer 
of two electrons to oxygen, forming hydrogen peroxide [57]. The enzyme is sluggish with a 
low catalytic rate constant ranging from 0.2 sec-1 to 0.8 sec-1 and Km values in the low 
micromolar range for both the substrates PNP and PMP [28,55,56]. The product PLP has a 
greater affinity than either of the substrates, suggesting that it may function as a product 
inhibitor of the enzyme [28,58,59]. 
The crystal structure of the human enzyme, as well as those from other species have been 
determined, all of which show a similar two-fold related dimer with two FMN molecules 
bound at the dimer interface making non-covalent interactions with both subunits (Figure 5) 
[55-57,60,61]. Mutations of key amino acid residues can affect folding of the enzyme into a 
form with diminished activity or no activity, can strongly influence the binding affinity of 
substrates, can reduce the affinity for the cofactor FMN and can affect catalytic activity. 
Knowing the residues involved in substrate and cofactor binding and in the catalytic 
mechanism is of paramount importance for understanding the function of PNPOx. 
 
Fig. 5. Three-dimensional structure of human PNPOx complexed with the cofactor (FMN,  
in grey) and the product (PLP, in yellow). The two monomers forming the homodimeric 
structure of the protein are colored magenta and cyan.  
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In the structure of human PNPOx, the isoalloxazine ring of FMN is involved in both 
hydrophobic and hydrogen-bond interactions with both subunits (monomers) of the protein, 
including Thr111, Glu174, Phe110, Leu98 and Met96 (Figure 6) [56]. The FMN ribityl group 
makes hydrogen-bond interactions with Met96, Gln139, Trp219, Pro261, Trp219, Lys117, 
Glu217, Gln174, Arg229, Arg138 and Arg141. The FMN phosphate moiety, which is located 
deeper into the protein structure, makes hydrogen-bond/salt-bridge interactions to Arg95, 
Arg141, Arg161, Ser175, Arg116, Lys117 and Arg229. The substrate PNP, as well as the 
product PLP, binds at the re-face of the bound FMN, where the PLP pyridine ring stacks 
parallel against the pyrazine and pyrimidine portions of the FMN isoalloxazine ring with 
extensive van der Waals contacts between the two, with the C4’ of PLP and N5 of FMN 
separated by about 3.4 Å (Figure 6). The phosphate moiety of PLP, which extends toward the 
surface of the binding pocket, makes salt bridges and hydrogen bond interactions to Lys100, 
Arg161, Arg225, Tyr157 and Ser165. The O3'-hydroxyl group of PLP makes a hydrogen bond 
interaction to His227, while the carbonyl oxygen on C4' makes a water-mediated interaction to 
Glu77. Lastly, the pyridine nitrogen makes a water-mediated hydrogen bond interaction with 
Trp206. Not only do the interactions described above help stabilize FMN and substrate 
binding, but they also ensure correct orientation of FMN and PNP for substrate oxidation. 
Additionally, the interactions with both FMN and the substrate/product, which are at the 
interface of the two subunits, help stabilize the homodimeric structure.  
 
Fig. 6. The active site of human PNPOx, showing the bound PLP (yellow) at the re-face of 
the FMN (grey). The two monomers, forming the homodimeric structure of the protein, are 
colored magenta and cyan, respectively. For clarity, not all the residues interacting with the 
ligands are shown.  
www.intechopen.com
 
Molecular Defects of Vitamin B6 Metabolism Associated with Neonatal Epileptic Encephalopathy 
 
275 
3. PLP deficiency and NEE 
PLP deficiency due to dietary insufficiency is rare, since most dietary sources contain 
vitamin B6. Nonetheless, pathogenic mutations in the PNPO gene encoding for PNPOx are 
known to cause a reduced or null activity of PNPOx, resulting in PLP deficiency. Disruption 
of the salvage pathway can also occur by pathogenic mutations in the PL kinase gene or by 
drug induced inhibition of PNPOx and PL kinase enzymatic activity [5,6,62-67]. Metabolites 
that accumulate as a consequence of inherited defects in enzymes of other metabolic 
pathways and drugs are also known to form complexes with PLP and reduce its availability 
[1,67-70]. Since PLP must be metabolized by brain cells to meet the demand of newly 
synthesized apo-B6 enzymes disruption of the PLP salvage pathway could lead to improper 
functioning of PLP-dependent enzymes in the brain, resulting in neurological disorders, 
such as NEE.  
3.1 PNPOx deficiency-related NEE 
The most severe form of NEE has been found to be due to mutations in PNPOx, which lead to 
null or decreased activity of the enzyme. Observed mainly in Turkish and Asian populations, 
this syndrome, called PNPOx deficiency, shows symptoms such as fetal distress, 
hypoglycemia, anemia, acidosis and asphyxia [2,5-7,71]. This disorder is sometimes referred to 
as PLP-dependent NEE as individuals with PNPO deficiency respond only to PLP or PL 
therapy, and not to the other forms of vitamin B6, such as PN and PM. At least seven 
mutations in the PNPO gene, including homozygous missense, stop codon, nonsense, splice 
site and frameshift mutations have been identified to cause PLP-dependent NEE [5,6,62-67]. 
Most patients with these mutations are born prematurely and the disease can be fatal. 
Surviving children are usually mentally retarded and show an abnormal dependence on 
PLP/PL. The fact that these patients are unresponsive to treatment with PN but responsive to 
PL demonstrates that the defect is in PNPOx, which is required for PN conversion to PLP. 
Conversion of PL to PLP is achieved by PL kinase and does not require PNPOx activity 
(Figure 2). However, PLP from the diet has to be converted to PL by phosphatases, and is then 
reconverted to PLP in the cells by PL kinase. 
3.2 Pathogenic mutations in PNPOx  
The human PNPOx gene is situated on chromosome 17q21.2 [72], and several mutations in 
the gene have been implicated in NEE. In a study by Mills et al., the authors sequenced the 
PNPOx gene in patients with NEE and identified homozygous missense (R229W, in which 
the arginine residue in position 229 is substituted with a tryptophan residue), splice site 
(IVS3-1g > a) and stop codon (X262Q) mutations [5]. The stop codon and splice site 
mutations result in null PNPOx activity. The missense mutation (in genetics, defined as a 
point mutation in which a single nucleotide is changed, resulting in a codon that codes for a 
different amino acid) was reported to lead to ~70% reduction in PNPOx activity compared 
to the wild-type enzyme. Although significant, a 70% reduction in activity does not explain 
the observed drastic pathological effect in patients [5]. A later study showed the activity of 
the mutant enzyme to be almost null [66].  
Other PNPOx, including two novel homozygous missense mutations (R95H and R95C, in 
which arginine residue 95 is substituted by either a histidine or a cysteine) and a nonsense 
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mutation (A174X; a nonsense mutation is a point mutation in a sequence of DNA that 
results in a premature stop codon, or a nonsense codon in the transcribed mRNA, and in a 
truncated, incomplete, and usually nonfunctional protein product) have also been identified 
in several patients with classical symptoms of PLP-dependent NEE [5,6,62-67]. As will be 
discussed later, the elucidation of the crystal structure of PNPOx and the mechanism of PNP 
or PMP oxidation [57] have now contributed to the precise mechanism governing how some 
of these mutations lead to partial or complete loss of enzymatic function.  
3.3 Molecular basis of reduced enzymatic activity of PNPOx R229W and R95C 
mutants  
Our research group has carried out studies using site-directed mutagenesis, enzyme kinetics, 
X-ray crystallography and other functional studies aimed at understanding on a molecular 
level why PNPOx R229W and R95C mutants lead to reduced oxidase activity with the 
concomitant onset of NEE. The results from the R229W mutant have been published quite 
recently [66]. Arg229 is strictly conserved, and in the wild-type enzyme, this residue makes a 
short hydrogen-bond interaction with the FMN phosphate moiety (Figures 6 and 7). Arg229 
also makes both intra- and inter-subunit hydrogen-bond interactions with Arg141, Ser175, 
Glu217 and Ala260. Another interesting observation is that the side chain of Arg229 is 
sandwiched tightly between the residues Arg141, Glu217, Ala260, Trp219, Gln139, and Pro261.  
The R229W variant shows ~850-fold less catalytic efficiency than the wild-type enzyme due 
to a ~192-fold decrease in PNP affinity and ~4.5-fold decrease in the catalytic rate constant 
kcat. This shows that the in vitro activity of the R229 mutant enzyme is less than 0.2% of the 
wild-type enzyme, effectively making the activity so low that it will not function in the 
production of PLP from PNP. Fluorescence titration experiments also indicate an ~50-fold 
reduction in FMN affinity for the R229W mutant. Normally, wild-type PNPOx does not 
require the aadditional FMN to the assay because of its very tight binding. However, the 
mutant PNPOx loses even more activity unless FMN is added to the assay. Crystallographic 
studies showed that the substitution of the charged Arg229 residue with the larger 
tryptophan residue at the FMN binding site (Figure 7) has led to loss of hydrogen-bond and 
salt-bridge interactions with FMN. Additionally, the substitution with a bigger amino side 
chain has led to an alteration of the active site structure of PNPOx, resulting in loss of two 
critical hydrogen-bond interactions between PNP and the residues His227 and Arg225 
(Figure 7). These two hydrogen-bond interactions have previously been shown to be 
important for substrate binding and proper orientation for catalysis by allowing the PNP 
ring to orient parallel to the FMN ring [57]. Expectedly, in the ternary three-dimensional 
structure of the mutant enzyme, the PLP and FMN ring moieties have moved significantly 
apart and are no longer parallel to each other (Figure 7) [66]. The C4' of the substrate and N5 
of FMN are now separated by ~4.5 Å compared to the ~3.4 Å catalytic optimal position 
observed in the wild-type enzyme. In effect, the inability of Arg225 and His227 to make 
contact with the substrate has led to the destabilization of the substrate, preventing its 
proper orientation relative to FMN for efficient hydride transfer. 
In yet another study by our group (unpublished data) with the PNPOx R95C mutant, we 
have also observed a 4.8 fold decrease in kcat compared to the wild-type enzyme, and a ~70-
fold increase in Km, relative to the substrate PNP resulting in an ~341-fold decrease in the 
catalytic efficiency of the mutant enzyme compared to the wild-type enzyme. The FMN 
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affinity is also reduced by ~15% compared to the wild-type enzyme. Arg95 forms salt 
bridge/hydrogen bond interactions with the phosphate side chain of the FMN molecule 
utilizing two of the guanidinium group nitrogens (Figure 6), and the diminished binding of 
FMN to the enzyme may be a result of the loss of this interaction. In the absence of a crystal 
structure, we can only speculate that this mutation also leads to loss of several important 
interactions between the protein and PNP as evidenced by a decrease in PNP affinity, 
resulting in improper positioning of the substrate for optimal catalysis.  
 
Fig. 7. Superposition of the active site of R229W PNPOx mutant (cyan) with that of wild-
type PNPOx (magenta). Note the significant movements of the residues His227 and Arg225 
in the R229W mutant form, compared to the wild-type, resulting in the ligand PLP moving 
away from its optimal catalytic position. 
Neither of these mutations seems to have any significant effect on the secondary structure or 
thermal stability of the enzyme, even though affinity of the enzyme towards its cofactor 
FMN is diminished. These results provide molecular insight into how the R229W and R95C 
missense mutations affect PNPOx catalytic activity, and clearly explain why the treatment of 
NEE with PN is unsuccessful in patients with PNPOx mutants because of the inability of the 
enzyme to oxidize PNP (or PMP) to form PLP. The current treatment with PLP or PL is 
appropriate since the other enzyme involved in PLP metabolism, PL kinase, can convert PL 
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to PLP. Nevertheless, it’s clear that PLP made in the cell from PL is not enough, indicating 
that PL kinase alone and most likely PNPOx alone is not sufficient to meet the cell’s 
requirements and both the salvage pathway enzymes are necessary to provide adequate 
PLP to activate the many different apo-B6 dependent enzymes. It is possible, although yet to 
be proven, that the use of riboflavin (vitamin B2) and PN, in conjunction with PL, may offer 
some improvement over the current treatment protocol of PL or PLP alone due to the 
apparent loss of FMN from the PNPOx pathogenic variants. 
3.4 Predicting the molecular basis of reduced enzymatic activity of other PNPOx 
pathogenic mutants  
The precise mechanisms governing how the splice site (IVS3-1g > a), stop codon (X262Q), 
nonsense (A174X), and R95H missense mutations lead to partial or complete loss of PNPOx 
function are not known. Nevertheless, based on the crystal structure of PNPOx and the studies 
with the R95C and R229W mutants, several inferences can be made. In particular, it’s easy to 
predict how the mutant R95H may also affect the enzymatic activity based on the study with 
R95C. Although His95 may still be capable of forming hydrogen-bond interactions with the 
FMN phosphate, most likely the interaction would be weaker. Unlike the wild-type Arg, 
which makes a bidentate interaction with the FMN phosphate moiety, His can only utilize one 
of its nitrogens for interacting with the phosphate moiety. This mutation could also result in a 
decreased binding of PNP, as observed in the R229W and R95C mutants.  
In the splice site (IVS3-1g > a) mutation, the residues 122-139 are absent from the enzyme. Some 
of these residues are involved in the formation of the FMN binding cavity and interact with the 
cofactor. Others contribute to either a hydrophobic patch or a network of inter-dimer hydrogen-
bond interactions that stabilize the tertiary and quaternary structure of the wild-type protein. 
Notable among these residues are Asn124, Ser128, Tyr132, Glu134, Glu139, Asn137, Trp133, 
Phe131 and Leu129. Therefore, these amino acids are expected to be important for a proper 
tertiary fold, dimer stabilization, and binding of the cofactor for consequent catalysis. It is 
perhaps no surprise that the splice site mutation leads to total enzyme dysfunction.  
The abolition of the stop codon (X262Q) causes a C-terminal 28 amino acid extension 
(residues 262-289). The last residue at the C-terminus of the wild-type protein is the proline 
261, and is strictly conserved in all PNP oxidases. Pro261 is tucked at the dimer interface, 
and is located at the re-face of the FMN and directly underneath PNP (Figure 6). It’s likely 
that the C-terminus extension would result in at least the first five extended residues 
(Gln262, Leu263, Trp264, Asp265, Leu266) being accommodated at the dimer interface and 
more significantly occupy the substrate/product binding site permanently to inhibit 
substrate binding for catalysis. The extra 23 residues that extend from the active site may 
fold outside the dimer interface. On the other hand, if the 28-amino acid peptide extension 
does not fold as suggested above, it might disturb the dimer interface and result in the 
dissociation of the subunits into non-functional monomers. This mutation also results in a 
PNPOx with null activity. 
3.5 Clinical and general biochemical features of patients with PNPOx deficiency-
related NEE and management of the disorder 
There are several clinical features that manifest in patients with PNPOx deficiency-related 
NEE or PLP-dependent NEE. These include, but are not limited to, fetal distress, convulsion, 
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hypoglycemia, lactic acidosis, intractable seizures, hypoglycemia, acidosis, anemia, 
increased blood lactate, electroencephalogram with burst suppression pattern, and asphyxia 
[5,6,62-67]. Due to the severe deficiency of PLP, people with this disorder show reduced 
activity of several PLP-dependent enzymes, e.g. aromatic L-amino acid decarboxylase, 
ornithine aminotransferase, serine hydroxymethyltransferase, etc. As a result, cerebrospinal 
fluid (CSF), plasma and urine of these patients show deficient flux through PLP-dependent 
pathways [5,72], including lowered levels of homovanillic acid, 5-hydoxyindoleacetic acid 
and arginine; raised levels of 3-methoxytyrosine, L-DOPA, vanillacetate, glycine, threonine, 
histidine, ornithine and taurine. Most children with this disorder are born premature, 
progressively deteriorate and die within weeks if untreated. Surviving children are usually 
mentally retarded, and non-responsive to AEDs or pyridoxine, but dependent on a daily 
consumption of PLP to control the disease. This underscores the importance of promptly 
and properly diagnosing PNPOx deficiency-related NEE for correct pharmacological 
intervention.  
In a study by Wang et al. [73], the investigators gave 94 patients who were on AEDs, but still 
had intractable epilepsy, intravenous PLP, that was continued for another 3 days if seizures 
were controlled. Eleven of the patients responded to the intravenous PLP with complete 
control of the seizures. PLP was then replaced with oral pyridoxine in these patients and six 
relapsed. For patients who had a seizure relapse, the intravenous PLP was again 
administered followed by a daily oral PLP. AEDs were sequentially withdrawn and the 
patients remained on oral PLP. Three of the patients relapsed while three remained seizure 
free with withdrawal of the AEDs. Clinicians can use a similar protocol to diagnose PNPOx 
deficiency-related NEE. It’s also very important that after initial diagnosis of PLP 
dependency, there should be a follow-up to further confirm the diagnosis, i.e. whether the 
disorder is PNPOx deficiency related by carrying out a metabolic investigation, including 
screening the CSF for threonine and glycine levels, urine for vanillacetic acid levels and the 
CSF for neurotransmitters. Diagnosis should also be confirmed by mutational analysis of 
PNPOx genes. 
Hoffmann et al., have suggested an oral PLP dose of 30 mg/kg per day in three doses plus 
100 mg i.v. pyridoxine (in a single dose), plus 3-5 mg/kg folinic acid for treating PNPOx 
deficiency-related NEE [6]. The investigators found no therapeutic response with pyridoxine 
and folinic acid when used without PLP (the latter compound discussed in some detail 
later). In some instances, the above recommended PLP dose may have to be increased to 
effectively treat the disease [6]. As noted by Wang et al., [73], it may also require 
concomitant use of PLP and AEDs to effectively treat the disorder. Although not yet proven, 
it might also be useful to administer PLP/PL in conjunction with riboflavin (vitamin B2), the 
metabolic precursor of FMN since studies showed that mutations could drastically decrease 
the affinity of PNPOx for the FMN cofactor [66]. Against this backdrop is the potential of 
neurotoxic side-effects of too much PLP. 
3.6 Pyridoxine-dependent NEE and management of the disorder 
There are several cases of NEE where patients responded to treatment with pyridoxine. 
These PN-dependent NEE patients rarely show the severe fetal distress, elevated threonine 
and glycine, PLP-dependent enzyme deficiency, and premature birth that characterize 
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PNPOx deficiency-related NEE. PN-dependent NEE is an autosomal recessive disease of 
probably underestimated incidence, first described in 1954 [74], that is usually presented 
with neonatal epileptic encephalopathy. It is believed that lack of biological markers has 
contributed to the under diagnosis of several cases of PN-dependent NEE disorder [1]. 
Children with PN-dependent seizures have mutations in the ALDH7A1 gene (maps to 
5q31), which encodes for α-aminoadipic semialdehyde dehydrogenase (also called 
antiquitin). Sequencing of ALDH7A1 gene from individuals with pyridoxine-dependent 
seizures revealed homozygous as well as compound heterozygous mutations [75]. A 
comprehensive review of these mutations (missense, nonsense, splice-site and small 
deletions) has recently been provided by Scharer et al. [70]. One of these (E399Q, a missense 
mutation) is of particularly high frequency, and seems to alter cofactor binding and 
catalysis, having a significant impact on enzyme activity. 
Antiquitin functions as an aldehyde dehydrogenase within the cerebral lysine catabolism 
pathway by catalyzing the oxidation of α-aminoadipic semialdehyde, derived from 
pipecolic acid, to α-aminoadipic acid [70,75]. The abolished antiquitin activity thus results in 
accumulation of pipecolic acid, α-aminoadipic semialdehyde (α-AASA) and piperideine-6-
carboxylic acid (P6C) (Figure 8). P6C reacts with free PLP (Figure 8) forming a Knoevenagel 
condensation product depleting PLP, leading to an imbalance between the excitatory 
neurotransmitter glutamic acid and the inhibitory neurotransmitter GABA, thus providing 
an explanation for the observed seizures.  
As noted by Gospe, et al., patients with PN-dependent NEE are usually diagnosed by 
administration from one to five 100 mg doses of pyridoxine intravenously (under 
electroencephalography and vital-sign monitoring) during a clinical seizure, and noting 
prompt resolution of the clinical and electrographic features [4]. Alternatively, patients may 
be given 15 mg/Kg per day and noting complete control within a week [69,76]. For 
pyridoxine-deficient NEE, seizure relapse would occur after withdrawal of pyridoxine, but 
promptly controlled when re-administered. It’s important that AEDs are sequentially 
withdrawn to confirm the diagnosis. It should be noted that, if there is no improvement 
with pyridoxine administration, the patient should be promptly treated with PLP. Screening 
for PN-dependent seizures is also possible via determination of plasma pipecolic acid and 
by measuring urinary or plasma αAASA and P6C levels [77,78]. Diagnosis is also confirmed 
by mutational analysis of the antiquitin gene. Typically, onset of such seizures is in neonatal 
period or shortly thereafter with irritability. Those infants need to be treated using 
pharmacologic doses of pyridoxine and a life-long therapy is needed. Seizures recur upon 
pyridoxine withdrawal, and if untreated die from status epilepticus. The children with this 
disorder show mild to moderate developmental delay, and do very well even with a single 
intravenous dose of PN to prevent seizures [69].  
It’s quite possible that treatment with PL/PLP in the pyridoxine deficient NEE patients 
could also work, and physicians should consider combining both PN and PLP/PL therapy. 
A lysine-free diet has also been recommended for treating this disorder. While the rationale 
for a lysine restricted diet is clear (Figure 8), the clinical effect on the outcome in pyridoxine-
dependent seizures still has to be documented before this can be universally recommended. 
Pyridoxine treatment does not address the potential toxicity of accumulating pipecolic acid, 
αAASA and P6C.  
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Fig. 8. The interaction of lysine degradation intermediates with pyridoxal 5’-phosphate. 
Pyridoxine-dependent NEE is due to a deficient activity of antiquitin. 
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A few cases of neonatal epileptic encephalopathy have been reported to respond to 
treatment with folinic acid (5-formyl tetrahydrofolate, also known as leucovorin) [79,80]. 
These cases have been attributed to a distinct disorder with respect to pyridoxine-dependent 
epilepsy, until it was demonstrated that folinic acid-responsive patients also respond to 
pyridoxine, are antiquitin deficient and have mutations in the ALDH7A1 gene [80]. The 
response to folinic acid, which has been serendipitously discovered, is variable and is 
accompanied by a variable degree of responsiveness to pyridoxine. In our opinion, this 
observation, together with the fact that all folinic acid-responsive subjects showed the 
presence of two unidentified compounds in the cerebrospinal fluid, suggest that folinic acid-
responsive seizures, although related to pyridoxine-dependent epilepsy, might be 
considered a different condition. 
Another rare neonatal encephalopathy condition, the so-called hyperprolinemia type II, 
usually presented in childhood with fits and encephalopathy, is caused by the deficiency of 
the enzyme Δ1-pyrroline-5-carboxylate dehydrogenase, involved in proline degradation and 
encoded by the ALDH4A1 gene. This deficiency results in the accumulation of proline and 
L-Δ1-pyrroline-5-carboxylic acid in plasma and the consequent excessive excretion of the 
latter compound in urine [81]. L-Δ1-Pyrroline-5-carboxylic acid reacts in a Knoevenagel 
condensation with the aldehyde carbon of PLP, in a reaction similar to the one shown in 
Figure 8 for L-Δ1-piperideine-6-carboxylic acid [82,83]. The molecular mechanism of PLP 
depletion is indeed related to the one described before for the antiquitin-dependent epileptic 
encephalopathy. Seizures, which manifest in approximately half of the affected individuals, 
also respond well to pyridoxine treatment. 
4. Conclusions 
Neonatal epileptic encephalopathies are rare neurological disorders that may originate from 
PLP deficiency, owing to defects in the PNPOx enzyme of the vitamin B6 salvage pathway 
or in the antiquitin enzyme of the lysine degradation pathway. The basic metabolic faults of 
these two distinct causes of the disease are completely different. PNPOx defects slow down 
or block the conversion of PNP and PMP into PLP. Patients respond to treatment with PL or 
PLP but are insensitive to PN, and the disorder is usually referred to as PNPOx deficiency-
related or PLP-dependent NEE. On the other hand, antiquitin mutations result in the 
accumulation of metabolic intermediates that react with PLP to form complexes that do not 
permit activation of apo-B6 enzymes into their active holo-forms. Patients affected by 
antiquitin defects can be treated with any of the B6 vitamers (PN is the most used vitamer), 
since their salvage pathway is functioning correctly to produce PLP. Several different 
pathological mutations of PNPOx and antiquitin have been characterized in detail. In 
particular, our research group has characterized the missense mutations R95C and R229W 
of PNPOx. Patients affected by this disorder present several clinical and general features 
that are useful for diagnosing and managing the disease.  
Like NEE, several other neurological disorders, including seizures, autism, attention deficit 
hyperactive disorder, Alzheimer’s, Down Syndrome, schizophrenia, Parkinson’s, learning 
disability, anxiety disorders have also been associated with PLP deficiency [45,84-89]. This 
has inspired considerable interest in treating the symptoms of some of these disorders with 
vitamin B6. However, studies on the effect of B6 supplementation show conflicting results; 
some of the diseases have been responsive to PN or PLP/PL. For example PLP has been 
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successfully used in Japan in the treatment of a range of epilepsies from infantile spasms to 
status epilepticus [89,90]. PN has also been shown to improve drug-induced parkinsonism 
and psychosis in a schizophrenic patient [88]. Other studies have shown no such beneficial 
effect, although most of these studies were conducted with PN and not PL or PLP. It is quite 
clear that therapy with PN or PM in patients with a defective PNPOx will not be successful, 
because this enzyme is needed to oxidize PNP and PMP into PLP after the kinase has 
changed them into PNP and PMP. Also, therapy with PL, PN or PM in patients with a 
dysfunctional PL kinase will not work, because these vitamers would have to be 
phosphorylated by the kinase.  
It is also apparent from this review that neurological disorders, including epileptic episodes 
that are not responsive to conventional anticonvulsants could be due to mutations in either 
PNPOx, its salvage partner PL kinase or antiquitin. The genes coding for these enzymes are 
clearly candidates for mutational analysis in affected patients. If such an error is identified, 
studies could be performed to investigate the role of the mutations in the enzymatic activity 
and the associated phenotypes. This perhaps would point to the correct pharmacologic 
intervention.  
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